Aclarion Reports 196% Annual Scan Volume Growth in Q1 2026, Signaling Accelerating Clinical Adoption

Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, reported first quarter 2026 results highlighted by a 196% year-over-year increase in Nociscan scan volumes, reflecting accelerating clinical adoption and integration into clinical workflows. The company also achieved 64% sequential scan volume growth compared to Q4 2025, driven by new account activations and deeper utilization within existing sites.

The growth underscores the value proposition of Nociscan, a platform that uses biomarkers and augmented intelligence to help physicians identify the location of chronic low back pain. With approximately 5.8 million lumbar MRIs performed annually in the U.S. for low back pain, Aclarion believes Nociscan addresses a potential $2 billion market opportunity. Repeat usage trends suggest increasing physician confidence in the technology, positioning the company for sustained expansion.

Key catalysts include early payer adoption in the U.K., where Nociscan has been reimbursed by Vitality, AXA, and Aviva—three of the four largest private insurers. The company also launched a targeted direct-to-patient campaign in the U.K., featuring a video with Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic. In the U.S., Aclarion continues to engage with payers through its Nociscan Reimbursement Program to establish coverage pathways.

On the clinical front, Aclarion is advancing the CLARITY randomized trial, designed to validate the clinical utility of Nociscan in guiding treatment decisions. A preliminary internal readout is expected in the second half of 2026, with public disclosure of early interim results anticipated in late 2026. The company also has seven ongoing clinical trials and multiple investigator-initiated real-world evidence trials to support reimbursement discussions and potential local coverage decisions by commercial insurers.

Aclarion strengthened its intellectual property portfolio with a newly issued patent covering the use of AI in workflows of future products, bringing the total to 64 issued and pending patents worldwide. This reinforces the company's competitive moat and ability to scale while maintaining strong gross margins.

Financially, Aclarion enters this growth phase with a solid foundation. As of March 31, 2026, the company held $19.0 million in cash with no debt and a clean capital structure. With 2,444,871 common shares outstanding (2,882,371 fully diluted), cash per share stands at approximately $6.60 on a fully diluted basis. A recently announced $2.5 million share repurchase program, combined with current cash resources, is expected to fund operations into the second half of 2027.

“Q1 represents a clear inflection for Aclarion,” said Brent Ness, Chief Executive Officer. “Scan volume growth accelerated significantly, driven by increasing physician adoption and stronger execution with our recently hired Commercial Directors in the UK and the Eastern US. Importantly, we are still in the early stages of commercializing Nociscan into a large and underpenetrated market.”

For more information, visit the company's newsroom at Aclarion Newsroom.